Abstract
We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.
Author supplied keywords
Cite
CITATION STYLE
Stanchina, M., Pastore, A., Devlin, S., Famulare, C., Stein, E., & Taylor, J. (2019). CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A. Journal of Hematology and Oncology, 12(1). https://doi.org/10.1186/s13045-019-0771-0
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
